Эффективность и приемлемость влагалищной комбинированной гормональной системы, содержащей этинилэстрадиол и этоногестрел. Обзор литературы

1. Руководство по контрацепции. Под ред. В.Н.Прилепской. Изд. 5-е, доп. М.: МЕДпресс-информ, 2018.
[Rukovodstvo po kontratseptsii. Pod red. V.N.Prilepskoi. Izd. 5-e, dop. Moscow: MEDpress-inform, 2018 (in Russian).]
2. Сакевич В.И. От аборта к контрацепции. Демоскоп Weekle. 2016; 687–88.
[Sakevich V.I. Ot aborta k kontratseptsii. Demoskop Weekle. 2016; 687–88 (in Russian).]
3. Всемирная организация здравоохранения. Медицинские критерии приемлемости методов контрацепции. ВОЗ, Европейское региональное бюро, 2015. ISBN 978-92-8-9052689
[Vsemirnaia organizatsiia zdravookhraneniia. Meditsinskie kriterii priemlemosti metodov kontratseptsii. VOZ, Evropeiskoe regional'noe biuro, 2015. ISBN 978-92-8-9052689 (in Russian).]
4. Canadian Contraception Consensus. SOGC Clinical Practice Guideline J Obs Gynecol Can 2004; 143: 219–54.
5. Тарасова М.А. Программа CHOICE – «Здоровая контрацепция» – в России. Оржин. 2009; 1: 12–4.
[Tarasova M.A. Programma CHOICE – "Zdorovaia kontratseptsiia" – v Rossii. Orzhin. 2009; 1: 12–4 (in Russian).]
6. Доброхотова Ю.Э., Затикян Н.Г. Сексуальная жизнь и влагалищная контрацептивная рилизинг-система. РМЖ. 2007; 15 (17): 1286–8.
[Dobrokhotova Iu.E., Zatikian N.G. Seksual'naia zhizn' i vlagalishchnaia kontratseptivnaia rilizing-sistema. RMZh. 2007; 15 (17): 1286–8 (in Russian).]
7. Кумыкова З.Х. Консультирование как ключевой фактор при выборе гормональной контрацепции. Акушерство и гинекология. Новости, мнения, обучение. 2016; 2: 52–3.
[Kumykova Z.Kh. Konsul'tirovanie kak kliuchevoi faktor pri vybore gormonal'noi kontratseptsii. Akusherstvo i ginekologiia. Novosti, mneniia, obuchenie. 2016; 2: 52–3 (in Russian).]
8. Lete I, Cuesta MC, Marín JM, Guerra S. Vaginal health in contraceptive vaginal ring users – A review. Eur J Contracept Reprod Health Care 2013; 18: 234–41.
9. López-Picado A, Lapuente O, Lete I. Efficacy and side-effects profile of the ethinylestradiol and etonogestrel contraceptive vaginal ring: a systematic review and metaanalysis. Eur J Contracept Reprod Health Care 2017; 22 (2): 131–46.
10. Frost JJ, Lindberg LD. Reasons for using contraception: perspectives of US women seeking care at specialized family planning clinics. Contraception 2013; 87: 465–472.
11. Ahrendt HJ, Nisand I, Bastianelli C et al. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 mkg of ethinyl estradiol and 3mg of drospirenone. Contraception 2006; 74: 451–7.
12. Duijkers I, Killick S, Bigrigg A et al. A comparative study on the effects of a contraceptive vaginal ring NuvaRingV® and an oral contraceptive on carbohydrate metabolism and adrenal and thyroid function. Eur J Contracept Reprod Health Care 2004; 9: 131–40.
13. Sabatini R, Cagiano R. Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Contraception 2006; 74: 220–3.
14. Egarter C, Frey Tirri B, Bitzer J et al. Women's perceptions and reasons for choosing the pill, patch, or ring in the CHOICE study: a cross-sectional survey of contraceptive method selection after counseling. BMC Womens Health 2013; 13: 9. DOI: 10.1186/1472-6874-13-9
15. Lete I, Doval JL, Perez-Campos E et al. Self-described impact of noncompliance among users of a combined hormonal contraceptive method. Contraception. 2008; 77: 276–82.
16. Roumen FJ, Dieben TO. Comparison of uterine concentrations of ethinylestradiol and etonogestrel – after use of a contraceptive vaginal ring and an oral contraceptive. Fertil Steril 2006; 85: 57–62.
17. Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception 1995; 51: 283–288.
18. Oddsson K, Leifels-Fischer B, Wiel-Masson D et al. Superior cycle control with f cjntraceptive vaginal ring compared with an oral contracetive containing 30 mkg ethynylestradiol and 150 mkg levonorgestrel a randomized trial. Hum Reprod 2005; 20: 557–62.
19. Jain S, Vaid NB, Narang Y et al. A Randomised Controlled Trial Comparing the Efficacy and Side-Effects of Intravaginal Ring (Nuvaring(®)) With Combined Oral Hormonal Preparation in Dysfunctional Uterine Bleeding. J Clin Diagn Res 2016; 10 (3): QC21-4.
20. Veres S, Miller L, Burington B. A comparison between the vaginal ring and oral contraceptives. Obstet Gynecol 2004; 104: 555–63.
21. Weisberg E, Merki-Feld GS, McGeechan K et al. Randomized comparison of bleeding patterns in women using a combined contraceptive vaginal ring or a low-dose combined oral contraceptive on a menstrually signaled regimen. Contraception 2015; 91: 121–6.
22. Agarwal N, Gupta M, Kriplani A et al. Comparison of combined hormonal vaginal ring with ultralow-dose combined oral contraceptive pills in the management of heavy menstrual bleeding: a pilot study. J Obstet Gynaecol 2016; 36: 71–5.
23. Mohamed AM, El-Sherbiny WS, Mostafa WA. Combined contraceptive ring versus combined oral contraceptive (30-lg ethinylestradiol and 3-mg drospirenone). Int J Gynaecol Obstet 2011; 114: 145–8.
24. Bustillos-Alamilla E, Zepeda-Zaragoza J, Hernandez-Ruiz MA, et al. Anticoncepcion con hormonales combinados en ciclos extendidos artificialmente. Ginecol Obstet Mex 2010; 78: 37–45.
25. Dieben TO, Roumen FJ, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol 2002; 100: 585–93.
26. Прилепская В.Н., Назарова Н.М., Бестаева Н.В. Микробиоценоз влагалища и контрацептивное кольцо. Вопр. гинекологии, акушерства и перинатологии. 2012; 11 (1): 75–8.
[Prilepskaia V.N., Nazarova N.M., Bestaeva N.V. Mikrobiotsenoz vlagalishcha i kontratseptivnoe kol'tso. Vopr. ginekologii, akusherstva i perinatologii. 2012; 11 (1): 75–8 (in Russian).]
27. Минкина Г.Н. Гормональные контрацептивы и риск цервикальной неоплазии. Вопр. гинекологии, акушерства и перинатологии. 2013; 12 (1): 56–63.
[Minkina G.N. Gormonal'nye kontratseptivy i risk tservikal'noi neoplazii. Vopr. ginekologii, akusherstva i perinatologii. 2013; 12 (1): 56–63. (in Russian).]
28. WHO study, 2013.
29. Verhoeven CH, van den Heuvel MW et al. The contraceptive vaginal ring, NuvaRing, and antimycotic co-medication. Contraception 2004; 69 (2): 129–32.
30. Dogterom P, van den Heuvel MW, Thomsen T. Absence of Pharmacokinetic Interactions of the Combined Contraceptive Vaginal Ring Nuva­Ring with Oral Amoxicillin or Doxycycline in Two Randomised Trials. Clin Pharmacokinetics 2005; 44 (4): 429–38.
31. Haring T, Mulders TM. The combined contraceptive ring NuvaRing and spermicide co-medication. Contraception 2003; 67 (4): 271–2.
32. Прилепская В.Н. НоваРинг – контрацепция, анатомия, сексология. Гинекология. 2004; 6 (6).
[Prilepskaia V.N. NovaRing – kontratseptsiia, anatomiia, seksologiia. Ginekologiia. 2004; 6 (6). (in Russian).]
33. Sabatini R. NuvaRing and sexual comfort. Giornale Italiano di Ostetrica e Ginecologia 2004; 26 (7): 321–3.

________________________________________________

1. Rukovodstvo po kontratseptsii. Pod red. V.N.Prilepskoi. Izd. 5-e, dop. Moscow: MEDpress-inform, 2018 (in Russian).
2. Sakevich V.I. Ot aborta k kontratseptsii. Demoskop Weekle. 2016; 687–88 (in Russian).
3. Vsemirnaia organizatsiia zdravookhraneniia. Meditsinskie kriterii priemlemosti metodov kontratseptsii. VOZ, Evropeiskoe regional'noe biuro, 2015. ISBN 978-92-8-9052689 (in Russian).
4. Canadian Contraception Consensus. SOGC Clinical Practice Guideline J Obs Gynecol Can 2004; 143: 219–54.
5. Tarasova M.A. Programma CHOICE – "Zdorovaia kontratseptsiia" – v Rossii. Orzhin. 2009; 1: 12–4 (in Russian).
6. Dobrokhotova Iu.E., Zatikian N.G. Seksual'naia zhizn' i vlagalishchnaia kontratseptivnaia rilizing-sistema. RMZh. 2007; 15 (17): 1286–8 (in Russian).
7. Kumykova Z.Kh. Konsul'tirovanie kak kliuchevoi faktor pri vybore gormonal'noi kontratseptsii. Akusherstvo i ginekologiia. Novosti, mneniia, obuchenie. 2016; 2: 52–3 (in Russian).
8. Lete I, Cuesta MC, Marín JM, Guerra S. Vaginal health in contraceptive vaginal ring users – A review. Eur J Contracept Reprod Health Care 2013; 18: 234–41.
9. López-Picado A, Lapuente O, Lete I. Efficacy and side-effects profile of the ethinylestradiol and etonogestrel contraceptive vaginal ring: a systematic review and metaanalysis. Eur J Contracept Reprod Health Care 2017; 22 (2): 131–46.
10. Frost JJ, Lindberg LD. Reasons for using contraception: perspectives of US women seeking care at specialized family planning clinics. Contraception 2013; 87: 465–472.
11. Ahrendt HJ, Nisand I, Bastianelli C et al. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 mkg of ethinyl estradiol and 3mg of drospirenone. Contraception 2006; 74: 451–7.
12. Duijkers I, Killick S, Bigrigg A et al. A comparative study on the effects of a contraceptive vaginal ring NuvaRingV® and an oral contraceptive on carbohydrate metabolism and adrenal and thyroid function. Eur J Contracept Reprod Health Care 2004; 9: 131–40.
13. Sabatini R, Cagiano R. Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Contraception 2006; 74: 220–3.
14. Egarter C, Frey Tirri B, Bitzer J et al. Women's perceptions and reasons for choosing the pill, patch, or ring in the CHOICE study: a cross-sectional survey of contraceptive method selection after counseling. BMC Womens Health 2013; 13: 9. DOI: 10.1186/1472-6874-13-9
15. Lete I, Doval JL, Perez-Campos E et al. Self-described impact of noncompliance among users of a combined hormonal contraceptive method. Contraception. 2008; 77: 276–82.
16. Roumen FJ, Dieben TO. Comparison of uterine concentrations of ethinylestradiol and etonogestrel – after use of a contraceptive vaginal ring and an oral contraceptive. Fertil Steril 2006; 85: 57–62.
17. Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception 1995; 51: 283–288.
18. Oddsson K, Leifels-Fischer B, Wiel-Masson D et al. Superior cycle control with f cjntraceptive vaginal ring compared with an oral contracetive containing 30 mkg ethynylestradiol and 150 mkg levonorgestrel a randomized trial. Hum Reprod 2005; 20: 557–62.
19. Jain S, Vaid NB, Narang Y et al. A Randomised Controlled Trial Comparing the Efficacy and Side-Effects of Intravaginal Ring (Nuvaring(®)) With Combined Oral Hormonal Preparation in Dysfunctional Uterine Bleeding. J Clin Diagn Res 2016; 10 (3): QC21-4.
20. Veres S, Miller L, Burington B. A comparison between the vaginal ring and oral contraceptives. Obstet Gynecol 2004; 104: 555–63.
21. Weisberg E, Merki-Feld GS, McGeechan K et al. Randomized comparison of bleeding patterns in women using a combined contraceptive vaginal ring or a low-dose combined oral contraceptive on a menstrually signaled regimen. Contraception 2015; 91: 121–6.
22. Agarwal N, Gupta M, Kriplani A et al. Comparison of combined hormonal vaginal ring with ultralow-dose combined oral contraceptive pills in the management of heavy menstrual bleeding: a pilot study. J Obstet Gynaecol 2016; 36: 71–5.
23. Mohamed AM, El-Sherbiny WS, Mostafa WA. Combined contraceptive ring versus combined oral contraceptive (30-lg ethinylestradiol and 3-mg drospirenone). Int J Gynaecol Obstet 2011; 114: 145–8.
24. Bustillos-Alamilla E, Zepeda-Zaragoza J, Hernandez-Ruiz MA, et al. Anticoncepcion con hormonales combinados en ciclos extendidos artificialmente. Ginecol Obstet Mex 2010; 78: 37–45.
25. Dieben TO, Roumen FJ, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol 2002; 100: 585–93.
26. Prilepskaia V.N., Nazarova N.M., Bestaeva N.V. Mikrobiotsenoz vlagalishcha i kontratseptivnoe kol'tso. Vopr. ginekologii, akusherstva i perinatologii. 2012; 11 (1): 75–8 (in Russian).
27. Minkina G.N. Gormonal'nye kontratseptivy i risk tservikal'noi neoplazii. Vopr. ginekologii, akusherstva i perinatologii. 2013; 12 (1): 56–63. (in Russian).
28. WHO study, 2013.
29. Verhoeven CH, van den Heuvel MW et al. The contraceptive vaginal ring, NuvaRing, and antimycotic co-medication. Contraception 2004; 69 (2): 129–32.
30. Dogterom P, van den Heuvel MW, Thomsen T. Absence of Pharmacokinetic Interactions of the Combined Contraceptive Vaginal Ring Nuva­Ring with Oral Amoxicillin or Doxycycline in Two Randomised Trials. Clin Pharmacokinetics 2005; 44 (4): 429–38.
31. Haring T, Mulders TM. The combined contraceptive ring NuvaRing and spermicide co-medication. Contraception 2003; 67 (4): 271–2.
32. Prilepskaia V.N. NovaRing – kontratseptsiia, anatomiia, seksologiia. Ginekologiia. 2004; 6 (6). (in Russian).
33. Sabatini R. NuvaRing and sexual comfort. Giornale Italiano di Ostetrica e Ginecologia 2004; 26 (7): 321–3.

Е.А. Межевитинова, В.Н. Прилепская*

ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. академика В.И. Кулакова» Минздрава России, Москва, Россия
*VPrilepskaya@mail.ru

________________________________________________

Elena A. Mezhevitinova, Vera N. Prilepskaya**

V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Moscow, Russia
*VPrilepskaya@mail.ru